Simply Wall St.
Amgen's (NASDAQ:AMGN) Shareholders Will Receive A Bigger Dividend Than Last Year
📈
AI Sentiment
Highly Positive
8/10
- Home
- AMGN
AMGN
Amgen Inc.
as of 12-15-2025 10:45am EST
$319.88
+$2.18
+0.69%
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Chart Type:
Time Range:
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | THOUSAND OAKS |
| Market Cap: | 181.7B | IPO Year: | N/A |
| Target Price: | $315.31 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Hold | Number of Analysts: | 14 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 12.93 | EPS Growth: | 65.12 |
| 52 Week Low/High: | $253.30 - $346.38 | Next Earning Date: | 02-03-2026 |
| Revenue: | $35,971,000,000 | Revenue Growth: | 10.56% |
| Revenue Growth (this year): | 10.85% | Revenue Growth (next year): | 1.71% |
AI-Powered AMGN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 16 hours ago
AI Recommendation
hold
Model Accuracy: 78.06%
78.06%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Amgen Inc. (AMGN)
Khosla Rachna
Sell
SVP, Business Development
AMGN Nov 12, 2025
Avg Cost/Share
$336.24
Shares
890
Total Value
$299,255.56
Owned After
7,082
SEC Form 4
Gordon Murdo
Sell
EVP, Global Commercial Ops
AMGN Nov 12, 2025
Avg Cost/Share
$336.83
Shares
6,879
Total Value
$2,317,071.46
Owned After
41,923
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Khosla Rachna | AMGN | SVP, Business Development | Nov 12, 2025 | Sell | $336.24 | 890 | $299,255.56 | 7,082 | |
| Gordon Murdo | AMGN | EVP, Global Commercial Ops | Nov 12, 2025 | Sell | $336.83 | 6,879 | $2,317,071.46 | 41,923 |
Latest Amgen Inc. News
AMGN Breaking Stock News: Dive into AMGN Ticker-Specific Updates for Smart Investing
MT Newswires
Morgan Stanley Adjusts Amgen Price Target to $304 From $329, Maintains Equalweight Rating
📊
AI Sentiment
Positive
7/10
Zacks
Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Amgen Says FDA Approves Uplizna For Autoimmune Disorder Treatment
📊
AI Sentiment
Positive
7/10
PR Newswire
FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Amgen Insiders Sell US$15m Of Stock, Possibly Signalling Caution
âž–
AI Sentiment
Neutral
4/10
MT Newswires
Wells Fargo Adjusts Price Target on Amgen to $325 From $300, Maintains Equalweight Rating
📊
AI Sentiment
Positive
7/10
Compare AMGN vs Leading Stocks
See how AMGN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AMGN Amgen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.